Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Capital Expenditures (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Capital Expenditures for 4 consecutive years, with $130000.0 as the latest value for Q4 2024.

  • Quarterly Capital Expenditures fell 77.23% to $130000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $130000.0 through Sep 2025, down 81.29% year-over-year, with the annual reading at $254000.0 for FY2024, 66.97% down from the prior year.
  • Capital Expenditures for Q4 2024 was $130000.0 at Werewolf Therapeutics, up from -$4000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.3 million in Q4 2022, with the low at -$1.6 million in Q3 2022.
  • Average Capital Expenditures over 4 years is $320750.0, with a median of $111000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 11838.46% in 2022, while the deepest fall reached 3477.27% in 2022.
  • Over 4 years, Capital Expenditures stood at $418000.0 in 2021, then surged by 690.43% to $3.3 million in 2022, then crashed by 82.72% to $571000.0 in 2023, then crashed by 77.23% to $130000.0 in 2024.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $130000.0, -$4000.0, and $17000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.